Drug Safety Review Needs Continued Input From OND Experts – Woodcock
This article was originally published in The Tan Sheet
Executive Summary
The potential for an independent drug safety office to cut off medical experts from postmarket review would be a major drawback to the proposal, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD
You may also be interested in...
Increased Authority, Funding Needed To “Fix The FDA,” Coalition Says
An ad campaign targeting inside-the-Beltway audiences seeks to pressure Congress for increased FDA funding
Increased Authority, Funding Needed To “Fix The FDA,” Coalition Says
An ad campaign targeting inside-the-Beltway audiences seeks to pressure Congress for increased FDA funding
Increased Authority, Funding Needed To “Fix The FDA,” Coalition Says
An ad campaign targeting inside-the-Beltway audiences seeks to pressure Congress for increased FDA funding